Dry Eye Disease and DEWS II – Ophthalmology Management
Dry eye disease (DED) affects millions of patients worldwide and is a common reason to seek eye care. A variety of DED therapies are available, but because DED varies in severity between patients no single therapy works for everyone. Evaluation and management of DED relying on evidence-based medicine is the best approach.
This article addresses the following questions:
- What guidelines exist regarding treatment?
- What does Medicare say about treatment of DED?
- We understand use of amniotic membrane therapy is heavily audited. Where does it come into the plan?
- Do payers typically reject claims for treatments that don’t adhere strictly to the steps outlined in DEWS II?
This article was published in Ophthalmology Management’s Coding & Reimbursement column, which is written by Corcoran’s Senior Consultant and Co-Founder, Suzanne Corcoran, COE. To view the entire article in Ophthalmology Management, click on the link below: